Dexmedetomidine + Propofol

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Conscious Sedation

Conditions

Conscious Sedation

Trial Timeline

Nov 1, 2005 → Aug 1, 2006

NCT ID

NCT00318955

About Dexmedetomidine + Propofol

Dexmedetomidine + Propofol is a approved stage product being developed by Pfizer for Conscious Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00318955. Target conditions include Conscious Sedation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04237792	Approved	Completed	Feb 18, 2020	Nov 30, 2021	MRI Sedation
NCT00538616	Phase 1/2	Completed	Jan 1, 2008	Apr 1, 2010	Brain Injury
NCT00318955	Approved	Completed	Nov 1, 2005	Aug 1, 2006	Conscious Sedation

Competing Products

2 competing products in Conscious Sedation

See all competitors

Product	Company	Stage	Hype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI	Eisai	Phase 3	77
Dexmedetomidine	Orion Corporation	Phase 3	74

Other Products from Pfizer